Catalent Signs Agreement To Sell Somerset, NJ Oral Solids Facility

Catalent, Inc. the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected to close in early 2025, have not been disclosed.

The Somerset facility also houses Catalent’s corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new location. The new location of the corporate headquarters will be announced at a later date.

In recent years, Catalent has invested in oral solid capabilities at other facilities in the United States and Europe, expanding its commercial spray drying capabilities, oral high potent API handling capabilities, and manufacturing capacity across its network. Most notably, in October 2022, Catalent acquired its 333,000-square-foot Greenville, NC facility for $475M. This state-of-the-art facility features fit-for-scale capacity with potent handling capabilities and specializes in turnkey solutions for oral solid dosage forms, including formulation development, analytical services, commercial manufacturing and packaging.